Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines.

de Brito Galvao JF, Kisseberth WC, Murahari S, Sutayatram S, Chew DJ, Inpanbutr N.

Am J Vet Res. 2012 Aug;73(8):1262-72. doi: 10.2460/ajvr.73.8.1262.

PMID:
22849687
2.

Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.

McMahon MB, Bear MD, Kulp SK, Pennell ML, London CA.

Am J Vet Res. 2010 Jul;71(7):799-808. doi: 10.2460/ajvr.71.7.799.

PMID:
20594083
3.

Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.

Jian W, Yamashita H, Levitt JM, Lerner SP, Sonpavde G.

Mol Cancer Ther. 2009 Jul;8(7):1772-8. doi: 10.1158/1535-7163.MCT-09-0141. Epub 2009 Jun 9.

4.

Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin.

Shang D, Liu Y, Matsui Y, Ito N, Nishiyama H, Kamoto T, Ogawa O.

Urology. 2008 Jun;71(6):1220-5. doi: 10.1016/j.urology.2007.11.029.

PMID:
18538698
5.

Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.

Marconato L, Zini E, Lindner D, Suslak-Brown L, Nelson V, Jeglum AK.

J Am Vet Med Assoc. 2011 Apr 15;238(8):1004-10. doi: 10.2460/javma.238.8.1004.

PMID:
21492043
6.

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.

da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos JĂșnior GA, Sakamoto-Hojo ET, Salvadori DM.

Exp Biol Med (Maywood). 2010 Jul;235(7):814-24. doi: 10.1258/ebm.2010.009322.

PMID:
20558835
7.

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

Denlinger CE, Rundall BK, Keller MD, Jones DR.

Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14.

PMID:
15464472
8.

Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.

Allstadt SD, Rodriguez CO Jr, Boostrom B, Rebhun RB, Skorupski KA.

J Vet Intern Med. 2015 Jan;29(1):261-7. doi: 10.1111/jvim.12533.

9.

Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.

DiPaola RS, Rubin E, Toppmeyer D, Eid J, Butzbach D, Dvorzhinski D, Capanna T, Cairdella M, Shih JW, Goodin S, Todd MB.

Med Sci Monit. 2003 Feb;9(2):PI5-11.

PMID:
12601301
10.

Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.

Fechner G, Perabo FG, Schmidt DH, Haase L, Ludwig E, Schueller H, Blatter J, Mller SC, Albers P.

Urology. 2003 Feb;61(2):468-73.

PMID:
12597983
11.

Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.

Bader Y, Hartmann J, Horvath Z, Saiko P, Grusch M, Madlener S, Maier S, Oehler L, Fritzer-Szekeres M, Heller N, Alken RG, Krupitza G, Szekeres T.

Cancer Lett. 2008 Feb 8;259(2):231-9. Epub 2007 Nov 26.

PMID:
18023527
12.

An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.

Smith JA, Brown J, Martin MC, Ramondetta LM, Wolf JK.

Gynecol Oncol. 2004 Jan;92(1):314-9.

PMID:
14751176
13.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA Jr.

Clin Breast Cancer. 2002 May;3 Suppl 1:12-6. Review.

PMID:
12057039
14.

Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.

Huang YT, Cheng CC, Lin TC, Chiu TH, Lai PC.

Oncol Rep. 2014 Feb;31(2):771-80. doi: 10.3892/or.2013.2882. Epub 2013 Nov 28.

PMID:
24297644
15.

Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder.

Chun R, Knapp DW, Widmer WR, DeNicola DB, Glickman NW, Kuczek T, Degortari A, Han CM.

J Vet Intern Med. 1997 Sep-Oct;11(5):279-83.

16.
17.
18.

Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.

Edelman MJ, Quam H, Mullins B.

Cancer Chemother Pharmacol. 2001 Aug;48(2):141-4.

PMID:
11561780
19.

The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells.

Strouch MJ, Milam BM, Melstrom LG, McGill JJ, Salabat MR, Ujiki MB, Ding XZ, Bentrem DJ.

Pancreas. 2009 May;38(4):409-15. doi: 10.1097/MPA.0b013e318193a074.

PMID:
19142175
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk